National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 1 of 2002)

Overview

The National Health Act 1953 was enacted to provide a framework for the administration of national health services and pharmaceutical benefits in Australia. This Act was introduced to address the need for a cohesive and effective system to manage health-related benefits and services across the nation. Enacted by the Australian Parliament, the Act aims to ensure that the public has access to necessary health services and medications in an equitable and efficient manner. The Pharmaceutical Benefits Declaration under subsection 85 (2AA) is one of the mechanisms through which the Act is implemented, allowing for the adjustment of the list of subsidised medications and treatments. This specific declaration, made by James McLaren Fox on behalf of the Department of Health and Ageing, serves to remove certain drugs and medicinal preparations from the scope of pharmaceutical benefits provided under the Act, thereby refining the list of subsidised items based on expert advice and evolving health needs.

Scope and Application

The Pharmaceutical Benefits Declaration under Subsection 85 (2AA) of the National Health Act 1953 applies to the specified drugs and medicinal preparations listed in the Schedule, effectively delisting them from the Pharmaceutical Benefits Scheme. This means that from the date of the declaration, 1 February 2002, the drugs "Aminogran Mineral Mixture", "Oestradiol Valerate and Oestradiol Valerate with Medroxyprogesterone Acetate", "Red-back Spider Antivenom", and "Streptokinase" will no longer be covered under Part VII of the National Health Act 1953, thus impacting their subsidy and availability under the Pharmaceutical Benefits Scheme. The declaration is made by James McLaren Fox, Acting Assistant Secretary of the Pharmaceutical Benefits Branch, Department of Health and Ageing, and Delegate of the Minister for Health and Ageing, following advice from the Pharmaceutical Benefits Advisory Committee. The geographic reach of this legislation is national, applying across the Commonwealth of Australia, and it affects entities and persons involved in the prescription, supply, and subsidy of these pharmaceutical products. The declaration does not specify any exclusions, exemptions, or thresholds other than the drugs listed in the Schedule, and its application is direct without the need for subordinate instruments.

Key Provisions

The main operative sections of this Declaration under subsection 85 (2AA) of the National Health Act 1953 (section 85(2AA)) involve the removal of certain drugs and medicinal preparations from the list covered by Part VII of the Act. Specifically, Section 2 of the Declaration states that the listed drugs and medicinal preparations will cease to be covered by Part VII as of 1 February 2002. The listed drugs include “Aminogran Mineral Mixture,” “Oestradiol Valerate and Oestradiol Valerate with Medroxyprogesterone Acetate,” “Red-back Spider Antivenom,” and “Streptokinase.” This means that from the specified date, these drugs will no longer be subject to the provisions of Part VII of the National Health Act 1953, which generally relate to the Pharmaceutical Benefits Scheme (PBS). The obligations imposed by this Act on the parties or entities it governs primarily concern the cessation of coverage for the listed drugs under the PBS. Once the Declaration takes effect, these drugs will no longer be subsidised under the scheme, meaning that they will not be available to patients at a reduced cost. Pharmaceutical companies, healthcare providers, and patients need to be aware of this change to avoid potential misunderstandings or financial implications. The Act also mandates that the Department of Health and Ageing, through its delegate, must ensure that the necessary administrative and informational updates are communicated effectively to all relevant parties to prevent any disruption in healthcare services. In terms of consequences for breach, the Act does not explicitly detail offences or penalties for non-compliance with the Declaration. However, the failure to adhere to the updated provisions might result in financial implications for patients who may need to pay full prices for these drugs, as well as potential administrative penalties for healthcare providers or entities that continue to claim subsidies for these medications after the effective date. There is no specific mention of maximum penalties in the text, but any breaches of health legislation typically attract fines or other sanctions as determined by relevant authorities.